Methods of Detecting Prostate Cancer
A method of detecting presence or absence of prostate cancer in a subject, both in vivo and ex vivo is disclosed. The method comprises analyzing mitochondria or a mitochondrial component in at least one prostate cell of the subject, whereby mitochondria an alteration in quantity and or characteristic is indicative of the presence or absence of the prostate cancer in the subject.
1 . A method of detecting presence or absence of prostate cancer in a subject, the method comprising analyzing mitochondria or a mitochondrial component of at least one prostate cell of the subject, whereby an alteration in quantity of a mitochondria or mitochondrial component and/or a characteristic of a mitochondria with respect to a normal prostate cell is indicative of the presence or absence of the prostate cancer in the subject.
2 . The method of claim 1 , wherein said mitochondrial component is selected from the group consisting of mitochondrial protein, mitochondrial glycoprotein, mitochondrial lipid, mitochondrial peptide and mitochondrial nucleic acid.
3 . The method of claim 2 , wherein said mitochondrial protein is an enzyme or a structural protein.
4 . The method of claim 1 , wherein said characteristic of said mitochondria is selected from the group consisting of mitochondrial size, mitochondrial mass, mitochondrial potential and mitochondrial volume.
5 . The method of claim 1 , wherein said analyzing comprises exposing said at least one cell to an agent capable of binding to, or accumulating in mitochondria.
6 . The method of claim 5 , wherein said exposing is effected in vivo.
7 . The method of claim 5 , wherein said exposing is effected ex vivo.
8 . The method of claim 5 , wherein said agent is labeled with a detectable moiety.
9 . The method of claim 8 , wherein said detectable moiety is selected from the group consisting of a polypeptide and a chemical.
10 . The method of claim 9 , wherein said polypeptide is selected from the group consisting of an enzyme, a fluorescent polypeptide and an epitope.
11 . The method of claim 9 , wherein said chemical is a radioactive isotope, a phosphorescent chemical, a chemiluminescent chemical and a fluorescent chemical.
12 . The method of claim 11 , wherein said radioactive isotope can be detected by radioimaging.
13 . The method of claim 11 , wherein said radioactive isotope is selected from the group consisting of Technetium 99m , Carbon 11 , Oxygen 15 , Nitrogen 13 , Rubidium 82 , Gallium 67 , Gallium 68 , Yttrium 90 , Molybdenum 99 , Iodine 123,124,131 Fluorine 18 , Phosphorus 32 , Copper 62 , Thallium 201 , Copper 64 , Copper 62 , Indium 111 , Xenon 133 .
14 . The method of claim 6 , wherein said agent is selected from the group consisting of Tc 99 Sestamibi, Tc 99 -tetrofosmin, Tc 99 -triphenylalkylphosphonium, 18-fluorine-labeled-2-fluoro-2-deoxyglucose, 62 Cu-diacetyl-bis(N4-methylthiosemicarbazone) and 64 Cu-1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N′″-tetraacetic acid—octreotide.
15 . The method of claim 6 , wherein said exposing is effected by intravenous administration of said agent.
16 . The method of claim 5 , wherein said analyzing further comprises imaging said agent.
17 . The method of claim 16 , wherein said imaging is selected from the group consisting of radioimaging, fluorescence imaging, color imaging, biophotonic imaging and magnetic resonance imaging.
18 . The method of claim 17 , wherein said radioimaging is selected from the group consisting of single photon emission computed tomography (SPECT), positron emission tomography (PET) and gamma cameras.
19 . The method of claim 7 , further comprising removing said at least one prostate cell from the subject prior to said analyzing.
20 . The method of claim 19 , wherein said removing is effected by a surgical biopsy procedure.
21 . The method of claim 7 , wherein said at least one prostate cell is intact.
22 . The method of claim 7 , wherein said at least one prostate cell is disintegrated.
23 . The method of claim 5 , wherein said agent is selected from the group consisting of a chemical, a dye, a peptide, a polypeptide and a polynucleotide.
24 . The method of claim 23 , wherein said dye is administered directly into said at least one prostate cell.
25 . The method of claim 23 , wherein said dye is membrane potential-independent.
26 . The method of claim 25 , wherein said membrane potential-independent dye is selected from the group consisting of nonyl acridine orange, MitoTracker Green FM, MitoFluor Green and MitoFluor Red 589.
27 . The method of claim 23 , wherein said dye is membrane potential-dependent.
28 . The method of claim 27 , wherein said membrane potential-dependent dye is selected from the group consisting of MitoTracker Orange CMTMRos, MitoTracker Orange CM-H 2 TMRos, MitoTracker Red CMXRos, MitoTracker Red CM-H 2 XRos, MitoTracker Red 580, MitoTracker Deep Red 633, MitoFluor Red 594, RedoxSensor Red CC-1 (2,3,4,5,6-pentafluorotetramethyldihydrorosamine, JC-1 probe (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide, Rhodamine 123, tetramethylrosamine, rhodamine 6G, tetramethylrhodamine methyl ester, tetramethylrhodamine ethyl ester, dihydrorhodamine, dihydrotetramethylrosamine, DiOC 2 (3), DiOC 5 (3), DiOC 6 (3), DiSC 3 (5), DiIC 1 (5), DASPMI (4-Di-1-ASP), DASPEI and CoroNa Red Na + .
29 . The method of claim 23 , wherein said polypeptide is selected from the group consisting of an antibody an avidin and a derivative thereof.
30 . The method of claim 29 , wherein said avidin derivative is selected from the group consisting of avidin, strepavidin and nutravidin.